Could a pill replace IV therapy for MDS? new study investigates
NCT ID NCT06091267
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares an oral drug (ASTX727) to an intravenous (IV) drug (decitabine) in 72 Chinese adults with myelodysplastic syndromes (MDS), a bone marrow disorder. Participants will receive both treatments in a crossover design to see if the pill works as well as the infusion. The goal is to find a more convenient treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASTX727 (decitabine and cedazuridine)
What this could lead to
If it works, this could offer a more convenient oral treatment option for myelodysplastic syndromes, potentially replacing the need for IV infusions.
What could go wrong
This is an early-phase study with only 72 participants, so results may not be conclusive. The oral drug might not be as effective or could have different side effects than the IV version.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital,Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China